MOLBIO DIAGNOSTICS LTD vs TORRENT PHARMACEUTICALS L
A side-by-side comparison of MOLBIO DIAGNOSTICS LTD (MOLBIO) and TORRENT PHARMACEUTICALS L (TORNTPHARM) — valuation, profitability, growth, and financial health — to help you judge which is the stronger buy today.
On the numbers, TORRENT PHARMACEUTICALS L leads MOLBIO vs TORNTPHARM on 9 of 14 metrics. See the breakdown below — the right pick still depends on your goals (value vs growth, risk appetite).
- Valuation13
- Profitability13
- Growth20
- Size & financial health13
Each axis shows this group's split of that metric, scaled so the leader sits at the edge. Relative to each other, not an absolute score.
Valuation
TORNTPHARM takes 3/4How expensive each stock is relative to its earnings and book value. Lower usually means cheaper.
Profitability
TORNTPHARM takes 3/4How efficiently each company turns capital and sales into profit. Higher is better.
Growth
MOLBIO takes 2/2Three-year compounded growth. Faster-growing businesses can justify a higher valuation.
Size & financial health
TORNTPHARM takes 3/4Scale and balance-sheet strength. Bigger revenue/profit and lower debt are generally safer.
- + []
- − ["The company has delivered a poor sales growth of 0.7% over past five years.", "The company has delivered a poor profit growth of -18.8% over past five years.", "Though the company is reporting repeated profits, it is not paying out dividend"]
- + ["Company has a good return on equity (ROE) track record: 3 Years ROE 26.2%", "Company has been maintaining a healthy dividend payout of 67.6%"]
- − ["Stock is trading at 19.37 times its book value", "Company has a high debt to equity ratio of 1.79."]
This comparison is for informational purposes only and is not investment advice. Please consult a SEBI-registered advisor before investing.